Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METATENSIN #4 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
250 mg orally twice daily
12-18 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine: extensively metabolized in liver via unidentified pathways; Hydralazine: N-acetylation (polymorphic NAT2), also hydroxylation and glucuronidation; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
95% bound to albumin and alpha-1-acid glycoprotein
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.5-1.0 L/kg; indicates moderate tissue distribution
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 60-80% (first-pass metabolism reduces from 100%)
70-90% (oral); 100% (IV).
No dosage adjustment required for renal impairment.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Severe hepatic impairment (Child-Pugh class C): Use with caution; reduce dose or prolong interval. Child-Pugh class A or B: No adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not established; safety and efficacy in children have not been studied.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Elderly patients may be more sensitive to hypotensive effects; initiate at lower dose (1 tablet) and titrate carefully.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Reserpine: mental depression, peptic ulcer, ulcerative colitis. Hydralazine: drug-induced lupus erythematosus, peripheral neuritis. Hydrochlorothiazide: electrolyte disturbances, hyperuricemia, acute angle-closure glaucoma, sulfonamide allergy cross-reactivity.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Reserpine: history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma, electroconvulsive therapy. Hydralazine: hypersensitivity, coronary artery disease, mitral valvular rheumatic heart disease. Hydrochlorothiazide: anuria, hypersensitivity to sulfonamide-derived drugs.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (bananas, oranges, salt substitutes) due to risk of hyperkalemia with methyldopa. Limit sodium intake for antihypertensive effect. Alcohol may potentiate orthostatic hypotension and sedation.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide diuretics are associated with a small increased risk of neural tube defects and cardiovascular anomalies; however, methyldopa is considered low risk for major malformations. Second trimester: Use may cause fetal electrolyte disturbances and thrombocytopenia. Third trimester: Thiazides can cause neonatal hypotension, hypoglycemia, bone marrow suppression, and volume depletion; methyldopa is associated with neonatal bradycardia and hypotension. Overall risk is considered moderate; alternative antihypertensives are preferred, especially in the first trimester.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Hydrochlorothiazide is excreted into breast milk in low concentrations (M/P ratio ~0.3), but its use may suppress lactation. Methyldopa is excreted into breast milk with M/P ratio approximately 0.3-0.5; infant exposure is low but may cause bradycardia or sedation. The combination should be used with caution during breastfeeding; monitoring the infant for signs of hypotension, electrolyte imbalance, and sedation is recommended.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
During pregnancy, the pharmacokinetics of methyldopa and hydrochlorothiazide may be altered due to increased plasma volume and renal blood flow. Initial dosing should be based on maternal weight. Methyldopa: Dose may need to be increased in second and third trimesters due to increased clearance; maximum dose 2 g/day. Hydrochlorothiazide: Avoid use in pregnancy due to risks; if absolutely necessary, dose should be minimized. Dose adjustments should be guided by maternal blood pressure response and fetal well-being.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Metatensin #4 is a combination of thiazide diuretic (hydrochlorothiazide 50 mg) and central alpha-agonist (methyldopa 500 mg). Use with caution in patients with renal impairment; monitor serum creatinine and electrolytes. Avoid abrupt discontinuation (risk of rebound hypertension). May cause positive Coombs test and hemolytic anemia (rare). Dose adjustment required in renal failure (Cr Cl <30 m L/min).
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Rise slowly from sitting or lying positions to prevent dizziness.,Avoid excessive sweating or dehydration; drink adequate fluids unless fluid-restricted.,Report unusual tiredness, fever, dark urine, yellowing of eyes/skin, or easy bruising/bleeding.,May increase blood sugar; monitor if diabetic.,Avoid alcohol, which can increase dizziness and drowsiness.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METATENSIN #4 vs ALDOCLOR-250, answered by our medical review team.
METATENSIN #4 is a Antihypertensive Combination that works by Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METATENSIN #4 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METATENSIN #4 is: 2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METATENSIN #4 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METATENSIN #4 is classified as Category C. METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.